Cas:549531-10-4 tert-butyl N-[(3R)-1-methyl-2-oxopyrrolidin-3-yl]carbamate manufacturer & supplier

Chemical Name:tert-butyl N-[(3R)-1-methyl-2-oxopyrrolidin-3-yl]carbamate

CAS.NO:549531-10-4

Synonyms:(R)-tert-Butyl (1-methyl-2-oxopyrrolidin-3-yl)carbamate;Carbamic acid, N-[(3R)-1-methyl-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester;2-Methyl-2-propanyl [(3R)-1-methyl-2-oxo-3-pyrrolidinyl]carbamate;tert-butyl 1-methyl-2-oxopyrrolidin-3-ylcarbamate

Molecular Formula:C₁₀H₁₈N₂O₃

Molecular Weight:214.262

HS Code:2933790090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:363.5±31.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.496

PSA:58.64000

Exact Mass:214.131744

LogP:0.37

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (R)-tert-Butyl (1-methyl-2-oxopyrrolidin-3-yl)carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 1-methyl-2-oxopyrrolidin-3-ylcarbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Carbamic acid, N-[(3R)-1-methyl-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester Use and application,Carbamic acid, N-[(3R)-1-methyl-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester technical grade,usp/ep/jp grade.

Related News: Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs. tert-butyl N-[(3R)-1-methyl-2-oxopyrrolidin-3-yl]carbamate manufacturer Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs. tert-butyl N-[(3R)-1-methyl-2-oxopyrrolidin-3-yl]carbamate supplier The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. tert-butyl N-[(3R)-1-methyl-2-oxopyrrolidin-3-yl]carbamate vendor The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. tert-butyl N-[(3R)-1-methyl-2-oxopyrrolidin-3-yl]carbamate factory In a memo to Branchburg employees on May 20, Nellie Clark, head of the plant, summed up the outside lawyers’ findings: “In the end and very importantly, allegations that Lilly made false statements to the FDA were not substantiated.”